Authors
Emma Taylor, Trevor Russell, Emma L Ballard, Haitham Tuffaha, Mohammadreza Amiri, Tamsin Mahoney, Semele Robinson, Ridzwan Namazie, Nadine E Foster, Anelise Silveira, Emmah Doig
Published in
Journal of hand therapy : official journal of the American Society of Hand Therapists. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
Carpal Tunnel Syndrome is the most common entrapment neuropathy resulting in high volume carpal tunnel release (CTR) surgeries. Usual hand therapy following CTR typically is offered in-person, in one-to-one sessions. Technology-enhanced, group-based hand therapy (TEG) may potentially reduce costs and increase access.
To determine the feasibility of the TEG approach and a future randomized controlled trial (RCT) comparing the clinical and cost-effectiveness of TEG versus usual care.
Single-centre feasibility and pilot RCT comparing TEG (group-based, app-based home-program, telehealth follow-up) versus usual care (one-to-one, paper-based home-program, in-person follow-up).
Outcomes included acceptability, feasibility, adherence, numbers screened/eligible/approached/randomized, follow-up rate and data completeness. Costs were calculated for both groups, and value of information analysis was conducted to assess the value of future research. Exploratory clinical outcomes included symptoms, pain and quality of life at baseline and 6-weeks follow-up. Patients' experiences were explored via survey.
Of 61 patients screened, 40 were eligible and approached, 33 randomized, 1 withdrew, resulting in 32 participants. 15 received usual care (M=53 years;73% female) and 17 received TEG (M=61 years;59% female). Acceptability (TEG M=4.33, usual care M=4.38) and feasibility (TEG M=4.47, usual care M=4.43) were high for both groups. TEG appointment attendance was 97% and home program completion 100% (n=4 missing). Most felt comfortable with the group format and valued peer interactions. Ease and convenience of the app-based home-program and telehealth follow-up were highly valued. Mean cost per participant for TEG was $68 and $110 for usual care. Symptoms improved in both groups similarly. Value of information analysis showed a future large RCT is expected to be cost-effective.
The TEG model was feasible and acceptable. Results indicate TEG is likely to lead to non-inferior clinical outcomes compared to usual care and has potential to save costs, justifying a future fully powered, multi-centre RCT.
PMID:
43015192
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0